US Fecal Microbiota Transplant Market – Rapidly Expanding Segment of Healthcare Sector

Release Date: 10-Oct-2019

Although various therapeutics are currently available in the market but all have some drawbacks, which results in development new therapeutic approaches such as microbiome based therapy. The use of microbiome as a novel therapeutic approach is gaining popularity among the patients and physician because of the high therapeutic potential and safety of this therapeutic. Fecal Microbiota Transplant is the only approved therapy of this segment, which is currently used for the management of C. difficile infection. Fecal Microbiota Transplant is a technique in which the microbiome present in the stool of healthy donor is isolated and introduced into the gut of the patient. In this way, it helps in restoration of the lost microbiome of the patient and boosts the immunity also.


According to the recent research report "US Fecal Microbiome Transplant Market Outlook 2025" by Kuick Research, the Fecal Microbiome Market in US is experiencing an exponential growth and it is emerging as a most rapidly growing therapeutic segment in the healthcare sector. The Analysis confirmed that besides the Yuck factor associated with the Fecal Microbiota Transplant, this therapy is widely accepting by the patients with C. difficile infection.


Download Report:


In the healthcare sector, Fecal Microbiota Transplant is emerging as a new therapeutic technique showing prominent action in the treatment of C. difficile infection, irritable bowel syndrome, Crohn’s disease and in treatment of some cancers also. FMT is currently used only for the management of C. difficile infection when the standard antibiotics are failed to treat the disease. As the incidence of C. difficile infection is continuously increasing in US, the market size of FMT is increasing rapidly. Further, FMT is also given in combination along with some antibiotics for treatment of infections, which is also indicating the high future demand of FMT in upcoming years.


Currently, a large number of Fecal Microbiome Therapeutics are in clinical trials by the leading pharmaceuticals companies, which is indicating a very bright future of US Fecal Microbiota Transplant market and also suggesting the future competitive landscape. Currently, clinical pipeline of Fecal Microbiota Transplant also involves an anticancer combination of Fecal Microbiota Transplant along with a checkpoint inhibitor, which is under phase II of Clinical Trial and conducted by 4D Pharma and Merck. The leading pharmaceutical players such as OpenBiome, Rebiotix, Finch Therapeutics, Maat Pharma, Seres Pharma, Vedanta, Pfizer, and Novartis etc. are working on the development of advanced Fecal Microbiota Transplant preparations. CP101 (lyophilized FMT capsules) and RBX2660 (FMT suspension) are the advanced FMT preparations, which are under clinical trial and are about to get FDA approval.


As per report finding, US Fecal Microbiota Transplant will emerge as a prominent and rapidly growing therapeutic market segment. Fecal Microbiota Transplant has shown tremendous success in the research area as well as commercial success also and most of the treatment methods in future will combine with FMT for enhancing the efficacy. Further, the number of Challenges for US FMT is less and they will overcome in short time while a large number of driving factors are boosting the market size at a tremendous rate. Further, our research also involves the availability of various FMT preparations, price analysis and other requirement for conducting this procedure. Therefore, the analysis of FMT market of US indicates a very bright future of this market segment.

Need custom market research solution? We can help you with that too.